Drugs Made In America Acquisition II Corp. DMII
$10.16
-$0.01-0.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.02M | 8.58M | 4.19M | -- | -- |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.62M | -9.07M | -4.60M | -- | -- |
| Change in Net Operating Assets | -676.20K | -627.40K | -607.60K | -- | -- |
| Cash from Operations | -1.28M | -1.11M | -1.02M | -- | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -500.00M | -500.00M | -500.00M | -- | -- |
| Cash from Investing | -500.00M | -500.00M | -500.00M | -- | -- |
| Total Debt Issued | 450.00K | 450.00K | -- | -- | -- |
| Total Debt Repaid | -533.80K | -533.80K | -533.80K | -- | -- |
| Issuance of Common Stock | 502.00M | 502.00M | 502.00M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -464.80K | -464.80K | -464.80K | -- | -- |
| Cash from Financing | 501.45M | 501.45M | 501.00M | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 170.60K | 340.70K | -16.80K | -- | -- |